SK Bioscience Co (XKRX:302440) COGS-to-Revenue : 0.83 (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co COGS-to-Revenue?

SK Bioscience Co's Cost of Goods Sold for the three months ended in Mar. 2025 was ₩128,424 Mil. Its Revenue for the three months ended in Mar. 2025 was ₩154,558 Mil.

SK Bioscience Co's COGS to Revenue for the three months ended in Mar. 2025 was 0.83.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. SK Bioscience Co's Gross Margin % for the three months ended in Mar. 2025 was 16.91%.

SK Bioscience Co COGS-to-Revenue Historical Data

The historical data trend for SK Bioscience Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co COGS-to-Revenue Chart

SK Bioscience Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.58

0.39

0.48

0.62

0.88

SK Bioscience Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.76	0.32	0.97	0.96	0.83

SK Bioscience Co COGS-to-Revenue Calculation

SK Bioscience Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	236569.373	/	267545.049
	=	0.88

SK Bioscience Co's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	128423.943	/	154557.716
	=	0.83

SK Bioscience Co (XKRX:302440) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

SK Bioscience Co's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	128423.943 / 154557.716
	=	16.91 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

SK Bioscience Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Bioscience Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbioscience.co.kr

SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co Headlines

No Headlines